HIV-associated neurological disorders: a guide to pharmacotherapy.
about
Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapyTargeting the Brain Reservoirs: Toward an HIV CureExpression of gp120 in mice evokes anxiety behavior: Co-occurrence with increased dendritic spines and brain-derived neurotrophic factor in the amygdala.Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitorsHIV-associated neurocognitive disorder.rhesus cytomegalovirus (macacine herpesvirus 3)-associated facial neuritis in simian immunodeficiency virus-infected rhesus macaques (Macaca mulatta).Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disordersAdjuvant therapies for HIV-associated neurocognitive disorders.Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development.Small endogenous molecules as moiety to improve targeting of CNS drugs.Lack of neuroinflammation in the HIV-1 transgenic rat: an [(18)F]-DPA714 PET imaging studyImpact of Tat Genetic Variation on HIV-1 DiseasePotent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disordersIdentification of functional modules of AKMT, a novel lysine methyltransferase regulating the motility of Toxoplasma gondii.Update on HIV-associated neurocognitive disorders.GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.Neuronal toxicity in HIV CNS diseaseNeurological Complications in Controlled HIV Infection.Proceedings of the ISEV symposium on "HIV, NeuroAIDS, drug abuse & EVs".MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K+ current conducted by KV1.3.Cannabinoid receptor-2 and HIV-associated neurocognitive disorders.8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.When do models of NeuroAIDS faithfully imitate "the real thing"?Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes.Neurological manifestations, laboratory and neuroimaging features in HIV-infected patients.Cross-sectional and longitudinal small animal PET shows pre and post-synaptic striatal dopaminergic deficits in an animal model of HIV.An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors.Temporal/compartmental changes in viral RNA and neuronal injury in a primate model of NeuroAIDS.HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.
P2860
Q27000422-7349DAF3-4F18-4CF1-9911-68752C730A58Q28075694-D5D29AA6-8674-4E7B-8A95-A5B68C327D8EQ30357525-1430CCA6-D67C-4157-A8C7-06D069EECFEDQ30625328-05064CDB-2D44-4C29-A68B-894F9F1161FBQ33939729-31A17A16-85F7-4A2D-8CFC-11DEFF9F7512Q34459321-F9D72E8C-BEB3-4652-BA59-63806977EFCAQ34507098-430C44BB-6EDC-4351-9A92-C935AF44CE72Q34692081-AF774AB1-9289-49FD-A232-42D18C5C4FE3Q35569236-1748661F-457B-4282-9143-C481E945CB5AQ35878624-05357F6B-C0FE-4BD0-8F24-20A0057D6D63Q35941437-62724C3E-16B2-4D1C-A886-A05C1DCEF1AEQ36065879-8D2241DE-C827-4721-95F6-5028B4B07E98Q36070781-4302A0A3-83D7-47BD-9816-CA3BC7D17C16Q36148507-1E2974DC-1EE0-420F-91D3-4987554FFF90Q36528651-C8C711BC-4E9B-4562-A312-FC1FC8756D55Q36868552-F1CEECAE-CF66-4690-9545-9F2448903461Q37086743-D684690C-FDC6-4DA2-9BE1-6670877096D0Q37200962-ED727A27-1184-489E-949E-6BBFA9ACFD9FQ37335823-F9A2F30A-2EDF-4970-810F-984206D20C64Q38101560-BAE6C688-4D64-4A7C-83CB-A230076BA402Q38154239-92076B9C-042B-4966-822E-8338E4786374Q40085989-84359847-3D96-4265-8FDB-7F2DF7790A36Q40219795-3C672A26-71EE-4E2C-AEE3-FD213A0CD4E1Q40462487-BA3A87E2-BFE0-40C8-B136-5A45A69CDBECQ42206762-CDBD0205-893D-4CF5-B57D-FAF7DC92A90CQ43419116-C6558334-7F76-4818-82C1-9E32CD5A3ADEQ47563724-CE57069F-BD4A-4BBB-A65A-9850FFB29D31Q47585560-6CACCBC7-4D65-4B89-9BC4-56BC873D34D2Q47604267-85C7C266-0058-4F80-BDD7-5025165A31E2Q47612809-4982AAB4-0D05-4670-8A3F-A8DA04AD4D4EQ50097601-27987AA8-C583-477E-9D58-A627CE683D4CQ54982714-5F0DAF6E-76BA-4A8D-8C7B-1B0C2B418B1EQ55432495-E5746A63-6E33-4BB8-94B6-9D30A1EC3490
P2860
HIV-associated neurological disorders: a guide to pharmacotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HIV-associated neurological disorders: a guide to pharmacotherapy.
@en
HIV-associated neurological disorders: a guide to pharmacotherapy.
@nl
type
label
HIV-associated neurological disorders: a guide to pharmacotherapy.
@en
HIV-associated neurological disorders: a guide to pharmacotherapy.
@nl
prefLabel
HIV-associated neurological disorders: a guide to pharmacotherapy.
@en
HIV-associated neurological disorders: a guide to pharmacotherapy.
@nl
P2860
P1433
P1476
HIV-associated neurological disorders: a guide to pharmacotherapy.
@en
P2093
Justin C McArthur
P2860
P304
P356
10.2165/11597770-000000000-00000
P577
2012-02-01T00:00:00Z
P6179
1028376649